Epizyme Inc

NASDAQ:EPZM  
2.07
-0.12 (-5.48%)
Other Pre-Announcement

Epizyme-Preliminary Tazverik Net Product Revenue To Be Between $11.2-$11.7 Million And Between $30.6-$31.1 Million For Q4 2021, FY 2021, Respectively

Published: 01/10/2022 12:24 GMT
Epizyme Inc (EPZM) - Epizyme-preliminary Tazverik Net Product Revenue Expected to Be Between $11.2-$11.7 Million and Between $30.6-$31.1 Million for 4q 2021, FY 2021, Respectively.
Epizyme-preliminary Tazverik Commercial Net Sales Expected to Be Between $7.0-$7.5 Million and Between $23.2-$23.7 Million for 4q 2021,fy 2021, Respectively.
Epizyme Inc - Continues to Expect Its Current Cash Runway to Extend Into Q4 of 2022.